In contrast to the immunosuppressive effects found in long-term high dosing, a study combining low-dose Everolimus (a rapamycin analog) and Dactolisib for a single 6 week course followed by influenza vaccination in healthy elderly patients (>65 years of age) found that this combination significantly reduced the number of infections reported by participants relative to placebo (from 2.41 to 1.49 infections per person per year), increased the serological response by more than 20%, did not produce any excess events of hyperglycemia or hypercholesteremia (associated with mTORC2 inhibition) and was generally well tolerated.